Efficient Early Drug Development for Ulcerative Colitis

Gastroenterology

Volumn 150, Issue 5, 2016, Pages 1056-1060

  Khanna, Reena ^a   Jairath, Vipul ^a,b   Casteele, Niels Vande ^a,c   Mosli, Mahmoud H ^a,d   Zou, Guangyong ^a   Parker, Claire E ^a   Levesque, Barrett G ^a,e   Sandborn, William J ^a,e   D'Haens, Geert ^a,f   Feagan, Brian G ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; MONOCLONAL ANTIBODY; PLACEBO; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

COLON BIOPSY; DISEASE ACTIVITY; DRUG DEVELOPMENT; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; PHARMACODYNAMICS; PHARMACOKINETICS; POST HOC ANALYSIS; PRIORITY JOURNAL; STUDY DESIGN; ULCERATIVE COLITIS; ANIMAL; BIOPSY; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; COLONOSCOPY; MASS COMMUNICATION; ORGANIZATION AND MANAGEMENT; PRECLINICAL STUDY; PREDICTIVE VALUE; PROCEDURES; REMISSION; TREATMENT OUTCOME; WORKFLOW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOPSY; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; COLONOSCOPY; DIFFUSION OF INNOVATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EFFICIENCY, ORGANIZATIONAL; GASTROINTESTINAL AGENTS; HUMANS; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; TREATMENT OUTCOME; WORKFLOW;

EID: 84964394205     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.03.013     Document Type: Editorial

References (22)

1. B.G. Levesque, W.J. Sandborn, J. Ruel, and et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice Gastroenterology 148 2015 37 51
2. DiMasi J. Innovation in the pharmaceutical industry: new estimates of R&D costs. Available: http://csdd.tufts.edu/files/uploads/Tufts-CSDD-briefing-on-RD-cost-study-Nov-18,-2014.pdf. Accessed November 5, 2015.
3. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 1987 1625 1629
4. J.H. Baron, A.M. Connell, and J.E. Lennard-Jones Variation between observers in describing mucosal appearances in proctocolitis Br Med J 1 1964 89 92
5. S.P. Travis, D. Schnell, P. Krzeski, and et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Gut 61 2012 535 542
6. B.G. Feagan, G.R. Greenberg, G. Wild, and et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin N Engl J Med 352 2005 2499 2507
7. B.G. Feagan, W.J. Sandborn, G. D'Haens, and et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis Gastroenterology 145 2013 149 157
8. V. Jairath, C.E. Parker, G. Zou, and et al. Placebo response and remission rates in ulcerative colitis clinical trials: systematic review and meta-analysis Gastroenterology 1 2015 S396
9. N.J. Horton, and G.M. Fitzmaurice Regression analysis of multiple source and multiple informant data from complex survey samples Stat Med 23 2004 2911 2933
10. S. Vermeire, S. O'Byrne, M. Keir, and et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial Lancet 384 2014 309 318
11. K.F. Froslie, J. Jahnsen, B.A. Moum, and et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort Gastroenterology 133 2007 412 422
12. K. Geboes, R. Riddell, A. Ost, and et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis Gut 47 2000 404 409
13. M.H. Mosli, B.G. Feagan, G. Zou, and et al. Development and validation of a histological index for UC Gut 2015 [E-pub ahead of print]
14. A. Marchal-Bressenot, J. Salleron, C. Boulagnon-Rombi, and et al. Development and validation of the Nancy histological index for UC Gut 2015 pii: gutjnl-2015-310187. http://dx.doi.org/10.1136/gutjnl-2015-310187. [Epub ahead of print].
15. I. Ordas, D.R. Mould, B.G. Feagan, and et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin Pharmacol Ther 91 2012 635 646
16. A.A. Fasanmade, O.J. Adedokun, M. Blank, and et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials Clin Ther 33 2011 946 964
17. N. Vande Casteele, M. Ferrante, G. Van Assche, and et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease Gastroenterology 148 2015 1320 1329
18. D.R. Mould, and R.N. Upton Basic concepts in population modeling, simulation, and model-based drug development CPT Pharmacometrics Syst Pharmacol 1 2012 e6
19. B.S. Boland, D.L. Boyle, W.J. Sandborn, and et al. Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis Aliment Pharmacol Ther 40 2014 477 485
20. L. Hansson, T. Hedner, and B. Dahlof Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point Blood Press 1 1992 113 119
21. D.A. Berry Bayesian clinical trials Nat Rev Drug Discov 5 2006 27 36
22. W. Hueber, B.E. Sands, S. Lewitzky, and et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Gut 61 2012 1693 1700